A Prospective Study to Observe Adverse Effects in Patients Receiving Anti-PD1 Immunotherapy

RecruitingOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

May 1, 2025

Study Completion Date

May 1, 2025

Conditions
ImmunotherapyADR
Trial Locations (1)

100000

RECRUITING

Xuanwu Hospital, Beijing

All Listed Sponsors
lead

Xuanwu Hospital, Beijing

OTHER